A new TRAIL in Alzheimer's disease therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling.Cells · 2024
   Review
2. Regulatory T Cell-Derived TRAIL Is Not Required for Peripheral Tolerance.ImmunoHorizons · 2021
   Article
3. Robust Sampling of Defective Pathways in Alzheimer's Disease. Implications in Drug Repositioning.International journal of molecular sciences · 2020
   Article
4. Microglia and Parkinson's disease: footprints to pathology.Journal of neural transmission (Vienna, Austria : 1996) · 2020
   Review
5. Evidence for a Pan-Neurodegenerative Disease Response in Huntington's and Parkinson's Disease Expression Profiles.Frontiers in molecular neuroscience · 2017
   Article
6. Clinical perspectives of TRAIL: insights into central nervous system disorders.Cellular and molecular life sciences : CMLS · 2016
   Review

Corrections and comments

• Comment on
  Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease.2015

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as